Metabolic syndrome does not affect sustained virologic response of direct-acting antivirals while hepatitis C clearance improves hemoglobin A1c

doi:10.4254/wjh.v10.i9.612

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 10, Issue 9

This Article

Academic Content and Language Evaluation of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (5675)

All Articles published online

The chart showing PDF series, WORD series, HTML series, Tables (1-6) series.

Item

Count

PDF

331

WORD

306

HTML

2287

Tables (1-6)

158

Sum=3082

Publishing Process of This Article

The chart showing Browse series, Download series.

Item

Count

Browse

1012

Download

1581

Sum=2593

Sep 27, 2018 (publication date) through Jul 21, 2024

Times Cited of This Article

Times Cited (13)

Journal Information of This Article

Publication Name

World Journal of Hepatology

ISSN

1948-5182

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Retrospective Study

World J Hepatol. Sep 27, 2018; 10(9): 612-621
Published online Sep 27, 2018. doi: 10.4254/wjh.v10.i9.612

Table 4 Mean difference in hemoglobin A1c by hepatitis C virus genotype and direct acting antiviral treatment

	Average change HbA1c (SE)	P-value
HCV genotype
1a	-0.73 (0.13)	0.97
1b	-0.69 (0.20)
2	-0.79 (0.27)
3	-0.88 (0.51)
4	-0.20 (NA)
Treatment
Sofosbuvir/Simeprevir	-0.71 (0.16)	0.97
Sofosbuvir/Ribavirin	-0.77 (0.27)
PrOD	-0.66 (0.15)
Ledipasvir/Sofosbuvir	-0.80 (0.24)

HbA1c: Hemoglobin A1c; HCV: Hepatitis C virus; PrOD: Ombitasvir/Paritaprevir/Ritonavir/ Dasabuvir

Citation: Dong TS, Aby ES, Benhammou JN, Kawamoto J, Han SH, May FP, Pisegna JR. Metabolic syndrome does not affect sustained virologic response of direct-acting antivirals while hepatitis C clearance improves hemoglobin A1c. World J Hepatol 2018; 10(9): 612-621
URL: https://www.wjgnet.com/1948-5182/full/v10/i9/612.htm
DOI: https://dx.doi.org/10.4254/wjh.v10.i9.612